TC BIOPHARM
TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life. TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
TC BIOPHARM
Industry:
Biotechnology Health Care Therapeutics
Founded:
2013-01-01
Address:
Holytown, North Lanarkshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.tcbiopharm.com
Total Employee:
51+
Status:
Active
Contact:
+4401414337557
Email Addresses:
[email protected]
Total Funding:
61.54 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon LetsEncrypt Amazon HSTS Google Analytics 4 Nginx
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Stock Details
Investors List
Renaissance Capital Partners
Renaissance Capital Partners investment in Venture Round - TC BioPharm
Crowdcube
Crowdcube investment in Equity Crowdfunding - TC BioPharm
Renaissance Capital Partners
Renaissance Capital Partners investment in Venture Round - TC BioPharm
Scottish Enterprise
Scottish Enterprise investment in Venture Round - TC BioPharm
Bluebird Bio
Bluebird Bio investment in Series B - TC BioPharm
Renaissance Capital Partners
Renaissance Capital Partners investment in Series B - TC BioPharm
Nipro Corporation
Nipro Corporation investment in Series A - TC BioPharm
Scottish Investment Bank
Scottish Investment Bank investment in Series A - TC BioPharm
SyndicateRoom
SyndicateRoom investment in Seed Round - TC BioPharm
NCL Technology Ventures
NCL Technology Ventures investment in Seed Round - TC BioPharm
Key Employee Changes
| Date | New article |
|---|---|
| 2023-01-30 | TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division |
Official Site Inspections
http://www.tcbiopharm.com Semrush global rank: 6.27 M Semrush visits lastest month: 1.06 K
- Host name: ams-a100-1181.arcusvps.net
- IP address: 185.193.216.181
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "TC BioPharm"
Company Overview - TC BioPharm
TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer.See details»
TC BioPharm Limited (TCBP)
Company TC BioPharm Limited Maxim 1 2 Parklands Way Holytown, Motherwell ML1 4WR United Kingdom T: +44 (0) 141 433 7557 [email protected]See details»
Company Information :: TC BioPharm Limited (TCBP)
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our …See details»
TC BioPharm - Crunchbase Company Profile & Funding
TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors.See details»
Management Team :: TC BioPharm Limited (TCBP)
Martin Thorp has been a member of the Board of directors since March 2016 and has served, in an executive capacity, as the Chief Financial Officer since March 2019. From December 2014, Martin was founder (and from 2018 chairman) of …See details»
TC BioPharm - LinkedIn
TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T ...See details»
TC Biopharm (Holdings) (TCBP) Company Profile & Description
Feb 11, 2022 Company profile for TC Biopharm (Holdings) Plc (TCBP) stock, with a description, list of executives, contact details and other key facts.See details»
TC Biopharm (Holdings - Overview, News & Similar companies
May 21, 2024 View TC Biopharm (Holdings (www.tcbiopharm.com) location in North Lanarkshire, United Kingdom , revenue, industry and description. Find related and similar …See details»
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and …
5 days ago The company is expected to reduce core operational burn by 55% when compared to 2024 EDINBURGH, Scotland, March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) …See details»
TC Biopharm (Holdings) Plc (TCBP) Company Profile & Facts
See the company profile for TC Biopharm (Holdings) Plc (TCBP) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
TC Biopharm 2025 Company Profile: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for TC Biopharm. Use the PitchBook Platform to explore the full profile.See details»
TC BioPharm - Craft
Oct 29, 2024 TC BioPharm has 5 employees across 4 locations. See insights on TC BioPharm including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Pipeline - TC BioPharm
TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer.See details»
TC Biopharm Announces Corporate Restructuring, Reduction in …
Mar 22, 2023 Extends cash runway Realigned to reflect corporate strategic vision EDINBURGH, Scotland, March 22, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or …See details»
TCBP Announces Transition from Nasdaq to OTC Markets
2 days ago TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell …See details»
Clinical • TC BioPharm
TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer.See details»
TC BioPharm To Outsource Several Functions; Annualized Savings …
5 days ago (RTTNews) - Biotechnology company TC BioPharm (Holdings) plc (TCBP) announced Tuesday initiatives to outsource several functions, moving to a more decentralized …See details»
TC BioPharm Announces Additional Cost Reduction Steps to …
Jan 3, 2024 TC BioPharm's Overhead Reduction Plan includes: Scaled down Research and Development to strictly process development for commercial applications and manufacturing …See details»
TC BioPharm Intends to Launch Preclinical Studies for Treatment …
Sep 6, 2024 Due to the highly infectious nature of monkeypox, TCBP expects to partner with a leading Infectious Disease Center or University associated with a similar organization to …See details»
Integrated Model - TC BioPharm
TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer.See details»